Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.
Comment: Published by Scroll Versions from space SCTC and version 3.1

Administrable Passive Immunizing Agents 

This content is designed for use when populating a record at the point of administration and includes concepts represented by the trade name (brand name) of the passive immunizing agent (immune globulin or antitoxin) that was administered to the Clientclient. It consists of concepts from the Proprietary Medicinal Product class and class and from the SNOMED CT Pharmaceutical CT Pharmaceutical / biologic product hierarchyproduct hierarchy, that  that are described using their trade name (brand name). 

Scope Definition: 

The scope of this subset is passive immunizing agents that are currently licensed for use in Canada and those obtained through special access programs. The subset includes concepts represented by the trade name (brand name) of the passive immunizing agent (immune globulin or antitoxin) that was administered to the client. The scope of this subset is all passive immunizing agents that have been licensed for use in Canada, those obtained through special access programs for use in Canada, and those that were never licensed in Canada (i.e., administered in other countries). Passive immunizing agents are used to facilitate protection against vaccine preventable infections, when vaccines are not available or are contraindicated or when vaccines have not been used before exposure to the infective agent. This content is intended to be used when populating a record at the point of administration.

General rules applied to this section 

  • The passive immunizing agents trade names will be represented as found in the
  • product monograph
  • Health Canada Drug Product Database (DPD) :it may be a mix of capital and lower-case letters;
  • In most cases, the product trade name will be represented as found in the product monograph or as listed on PHAC, CIG, Part 5, Passive Immunization web page : it may be a mix of capital and lower case letters. 
  • Image RemovedThere is a requirement to clarify this rule going forward in relationship to the ‘sources of truth’ prioritization, where the capitalization has not been compliant. 
  • NOTE: PHAC does not assign manufacturers’ abbreviations for the passive agents, as these products are managed on a province-by-province basis (versus nationally). Some of the manufacturers also produce vaccines, so the PHAC abbreviation is used in those cases.  For those manufacturers without a PHAC abbreviation: an abbreviation has been assigned by Infoway, using the PHAC abbreviation guidelines. A similar situation may occur with the vaccine product manufacturer abbreviations, as PHAC uses distributer, not manufacturer, so there may be gaps. Refer to Immunization Home Page - Main Reference Documentation section.
  • The product monograph is a reference for validation of detailed information.  

Fully Specified Name Fully Specified Name

The format for the Fully Specified Name (FSN) is as follows: 

  • Trade name(qualifier) Strength
 
  • Dose Form
 Manufacturer (product)
  • Marketing Authorization Holder (MAH) (real clinical drug)  
    • E.g.:HepaGam B
312
    •  312 international units per milliliterliquid for injection
 
    • Cangene Corporation(
product
    • real clinical drug) 

 FSN  FSN Components 

  • A qualifier may be added to FSN 

Preferred Synonym (English) 

For further details on PS, please refer to the Picklists guidelines 

The format for the Preferred Synonym (PS) is as follows: 

  • [PHAC/CHI Abbreviation Product
Abbreviation 
  • ] Trade name(qualifier)(strength)(Marketing Authorization Holder (MAH) Abbreviation if required)  
PHAC/CHI Manufacturer Abbreviation
    • e.g.:[HBIg] HepaGam B(STR) 
Cang

PS Components 

  • When adding a qualifier on the PS, it is not capitalized, unless otherwise represented in the product monograph. 

Preferred Synonym (French) 

  • La plupart des synonymes privilégiés en français sont les même qu’en anglais, à l’exceptions de certaines abréviations qui peuvent différer. 
  • Quand il n’a pas été possible de trouver une abréviation en français l’abréviation anglaise a été conservée.  
    • Par exemple :[CMVIg]Cytogam
  • CSL
    •  ou[BIG-IV]BabyBIG
  • CDPH
    •